Sclerosing encapsulating peritonitis associated with propranolol usage: A case report and review of the literature

Kalra, Sumit; Atia, Antwan; McKinney, Jason D.; Borthwick, Thomas; Smalligan, Roger D.

doi:10.1111/j.1751-2980.2009.00405.x

Cited by 11 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He was also on anti-retroviral medication, but there doesn't seem to be any causative link with the pathogenesis of SEP (Rivera 2007, Mesquita 2007). So his use of betablockers seems to be a possible cause of the SEP, which is consistent with the literature [3]. The classic beta blocker that was associated with SEP is practolol in 1974 [13], being withdrawn from the market in 1975.…”

Section: Daily Infusion Compounded In Multilayer Bagsupporting

confidence: 85%

“…The most common identified cause of this rare condition is continuous ambulatory peritoneal dialysis but other causes like beta blockers could be a cause as well (Table 1) [7][8]. Other associations reported in the literature include ovarian thecomas, tuberculous pelvic inflammatory disease, ventriculoperitonealshunts, systemic lupus erythematosus, orthotopic liver transplantation, protein S deficiency, ovarian cysts, keratoconjunctivitis sicca syndrome and various beta adrenergic blocking agents [3,5,[9][10][11][12][13].…”

Section: Daily Infusion Compounded In Multilayer Bagmentioning

confidence: 99%

“…The classic beta blocker that was associated with SEP is practolol in 1974 [13], being withdrawn from the market in 1975. Since then many case reported with other beta blockers like atenolol propranolol, timolol, metoprolol and sotalol [3,21]. Karla et al [3] described 2 patients who were receiving propranolol for 2 years and 2 months respectively and both developed SEP. Their doses were 320 mg and 80mg day, showing that the development of SEP is independent of the dose.…”

Section: Daily Infusion Compounded In Multilayer Bagmentioning

confidence: 99%

“…Membrane resection resulted in less patients having persistent bowel obstruction or death and the study recommended this be attempted when feasible. No surgical treatment was recommended in cases of associated ascites, asymptomatic sclerosing peritonitis, or sub-acute intestinal obstruction [2][3]26]. …”

Section: Daily Infusion Compounded In Multilayer Bagmentioning

confidence: 99%

“…Sclerosing Encapsulating Peritonitis (SEP) is a severe kind of peritonitis, relatively frequent in subjects submitted to peritoneal dialysis during the last 5 years [1][2]; other causes of the disease are shown in Table 1 [3]. Its treatment involves surgery for dealing with the obstruction, administering steroids and immunosuppressants, while there are only few cases describing the use of total parenteral nutrition (TPN) given as therapy for the management of SEP have been described (Kawanishi, many articles, Rajani) [4][5].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Review of the Literature and Description of a Case of Sclerosing Encapsulating Peritonitis Requiring Home Parenteral Nutrition

et al. 2011

View full text Add to dashboard Cite

We present a case of a 48 year old HIV patient, who had recurrent episodes of ascites since 2007. His history includes ischaemic heart disease, for which he was treated with atenolol from 2005 to 2007, and Type 2 diabetes; he was later started on propranolol 40mg twice a day from 2007 for Didanosine-induced portal hypertension. Because of negative cultures and neutrophil count < 250 cells/μL, spontaneous bacterial peritonitis was excluded. However, some low grade-peritoneal irritation cannot be ruled out because his CRP varied from 24 to 258, during 2007-2009, without any other obvious inflammatory cause. He was finally diagnosed in July 2009 with sclerosing encapsulating peritonitis (SEP) based on clinical features of intestinal obstruction, histology and imaging, including computed tomography and magnetic resonance imaging. Propranolol was stopped in November 2009. Because of the patient's severe intestinal obstruction, he was started on parenteral nutrition 2L/day. Since then, his CRP has returned to normal levels and there is a great improvement of his clinical features. This case demonstrates beta-blockers as a potential cause of SEP, while the presence of some low-grade peritoneal inflammation leading to SEP is also very likely.

show abstract

Section: Daily Infusion Compounded In Multilayer Bagsupporting

confidence: 85%

Section: Daily Infusion Compounded In Multilayer Bagmentioning

confidence: 99%

Section: Daily Infusion Compounded In Multilayer Bagmentioning

confidence: 99%

Section: Daily Infusion Compounded In Multilayer Bagmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Review of the Literature and Description of a Case of Sclerosing Encapsulating Peritonitis Requiring Home Parenteral Nutrition

et al. 2011

View full text Add to dashboard Cite

show abstract

Adhäsionen, sklerosierende Peritonitis und Mesenteritis

Offner

2013

Pathologie

View full text Add to dashboard Cite

Idiopathic encapsulating peritonitis: Report of two cases

Luz

Barral

et al. 2011

Surg Today

View full text Add to dashboard Cite

This report presents two cases of young males who developed the rare idiopathic form of sclerosing encapsulating peritonitis (SEP) presented as partial bowel obstruction, both diagnosed during surgical treatment, with satisfactory outcomes. Sclerosing encapsulating peritonitis is a rare and enigmatic condition, characterized by intraperitoneal fibrosclerosis, which causes intestinal obstruction. It is a chronic entity with a poorly elucidated pathophysiology, leading to the constitution of a thick white nacreous fibrosis membrane that wraps the bowel in a concertina-like fashion with some adhesions configuring an intra-abdominal cocoon. Sclerosing encapsulating peritonitis is reported in a wide variety of patients, including those who have undergone peritoneal dialysis, young adolescent girls, cirrhotic patients after peritoneal-venous shunting, and patients treated with β-blockers. Nevertheless, the etiology of SEP remains obscure. This entity presents many difficulties in preoperative diagnosis because of its peculiar characteristics. Recognition of the SEP results in proper management and prevents unnecessary bowel resection. Regardless of cause, the treatment of the obstruction is surgical, with dissection of the encasing membrane from the intestine and separation of adherent loops of small bowel until they are laid free and returned to their normal configuration. The prognosis after appropriate surgical therapy is good, but depends on coexisting diseases.

show abstract

Sclerosing encapsulating peritonitis associated with propranolol usage: A case report and review of the literature

Cited by 11 publications

References 30 publications

Review of the Literature and Description of a Case of Sclerosing Encapsulating Peritonitis Requiring Home Parenteral Nutrition

Review of the Literature and Description of a Case of Sclerosing Encapsulating Peritonitis Requiring Home Parenteral Nutrition

Adhäsionen, sklerosierende Peritonitis und Mesenteritis

Idiopathic encapsulating peritonitis: Report of two cases

Contact Info

Product

Resources

About